The quality of TCM injections even in door Save waste future disputes 
 
 
Years May 4 days at 10:30 source: http://www.pharmacy.hc360.com2015 medicine T 

    The CRC san-jiu automobil pharmaceutical industry network 】 【 (000999 SZ) core products "blood shu ning" injection after the recall, on April 25, jiangsu China pharmaceutical group co., LTD. (hereinafter referred to as "China pharmaceutical industry") production of "life vein injection" and adverse events were also revealed in guangdong, individual patients after symptoms of chills, fever.
 
    To this, the state drug administration (CFDA) has been reported to be recalled to the involved more than 30000 branch vein injection, and the confrontation pharmaceutical also will be announced in a week after the inspection results.
 
    TCM injections as a product of traditional Chinese medicine (TCM) modernization, because its make up for the traditional Chinese medicine oral or other ways to get effective slow shortcomings and once by market favour. However, the dosage form drug quality security incident occurred frequently, has once again aroused for many years in the industry of traditional Chinese medicine (TCM) injections waste future controversy.
 
    "Traditional Chinese medicine injection adverse events have been more, investigate its reason mainly is no clear standard in the field of traditional Chinese medicine (TCM). In addition, the link may also appear in actual application problem." Zhuo gen information pharmaceutical industry analyst said "to the 21st century economic report. "Injections of traditional Chinese medicines on the market at present basically follow the old formula, the future can only be in increasing investment on r&d guarantee security under the premise of realizing industrial upgrading."
 
    Traditional Chinese medicine (TCM) injections "grey area"
 
    According to the bulletin, the CFDA official website of China pharmaceutical production involved batch batch number is 14081413, "life vein injection" on August 14, 2014, the production, will expire on August 13, 2016. This batch drug totaled 37638, has been sold to jiangsu, zhejiang, guangdong, sichuan, xinjiang and other nine provinces (area).
 
    The batch "drug" is the heat caused by the original is not in conformity with the provisions after inspection. As a remedy, at present middle pharmaceutical has stopped the production of injection, the problem of production line and inventory of 53 batch product testing, testing results of publish to the society after a week.
 
    "Although this time is hot issues lead to halt production, but in the 'life vein injection in adverse reactions report itself always include chills, fever these adverse effects, in the test link is hard to define." "Pointed out that" may be a traditional Chinese medicine injection in production flaws or change in transportation and storage link drugs."
 
    Reporters refer to "life vein injection" from the middle jiangsu pharmaceutical instructions, in the column of the adverse reaction, made clear that have lead to allergic skin rash, low back pain, abdominal distension and other cases. In public information, the injection has marked "clinical reports have insomnia patients after medication, flush, sweat, chills, and even anaphylactic shock" of the case report.
 
    "National standard of TCM injections of traditional Chinese medicine extract generally look at only one or two main material, the appendages short detection standards temporarily. For many kinds of Chinese herbal medicine combination drug or some rare medicinal herbs, because it contains a lot of unknown substances, existing standards it is difficult to confirm its safety completely." Traditional Chinese medicine (TCM) industry analyst zhang told reporters.
 
    At present, China's traditional Chinese medicine injection drug standards level remains to be improved, by the local production standards into "national standard" related species is unqualified "areas" of the problem. According to figures from the industry report: currently, less than 3% of the varieties of the whole traditional Chinese medicine market TCM injections, but its adverse events accounted for about seventy percent of the whole traditional Chinese medicine industry.
 
    The qualitative problems in new drug research and development
 
    In recent five years, traditional Chinese medicine (TCM) injection of compound growth rate of about 22%, despite a drop in the growth of before, but still higher than 15.78% and the 18.23% increase in the drug market proprietary Chinese medicine. We have learned, now the domestic traditional Chinese medicine (TCM) injection has annual sales of more than 20 billion yuan, more than 400 production enterprises holding thousands of production approval, has a huge industrial chain.
 
    "In the emergency department and intensive, and other high-end medical market, traditional Chinese medicine injection curative effect of combination of Chinese and western, the advantage of fast obviously, market capacity and the gross margin level is considerable." Zhang told reporters that compared with the conventional used for anti-inflammatory injections of traditional Chinese medicines, qingrejiedu, market competitiveness is low, only to run to get profit.
 
    At present, the domestic has been through the national quality standard of traditional Chinese medicine injection has about 140 species, most of the varieties was developed in the eighty s. And in traditional Chinese medicine (TCM) injection into the "national standard", no more than 3 kinds of drugs of traditional Chinese medicine injection proportion is as high as 78.9%, low threshold of technology trade fight is very fierce.
 
    "Domestic Chinese medicine injection products is more on the basis of past experience to allocate production, in such aspects as safety, stability, difficult to qualitative, drug firms develop new varieties, is likely in the test this is not." "Said. "Drug ingredients, the more development process is complicated, the present situation of the now also affects the enthusiasm of the enterprise research and development."
 
    "Under pressure, frequent occurrence of adverse events industry for further transformation is inevitable. There still needs to be continued funding for future research and development production, with the scientific theory to control the risk, or industry upgrade." "Said.